FOLR1 and neoplasm: Of further interest is the potential of treating EOC with FRα and the PCFT dual-targeted antifolates, such as AGF94, that derive their tumor selectivity from their FRα and PCFT specificities over the ubiquitously expressed RFC [14,41,147,148,149].